WHO: at least 1 in 10 medicines in low- and middle-income countries is substandard or falsified
The WHO estimates at least 1 in 10 medicines in low- and middle-income countries is substandard or falsified.
The WHO estimates at least 1 in 10 medicines in low- and middle-income countries is substandard or falsified.

The World Health Organization's December 3, 2024 fact sheet on substandard and falsified medical products gives the scale of the problem and, usefully, a precise vocabulary.
The WHO draws a clear line between two failures. A substandard product is one that fails to meet its quality specifications — usually because of poor manufacturing or poor quality control. A falsified product is one that deliberately misrepresents its identity, composition, or source. The first is a failure of process; the second is a failure of honesty.
The estimated scale is large: about US$30.5 billion is spent each year on these products. They are most often sold online or in informal markets. A falsified product may contain no active ingredient, the wrong active ingredient, or the right one in the wrong amount.
The estimate — at least one in ten medicines in low- and middle-income countries — is a market-quality figure, not a single-product guarantee. But the mechanism it describes is universal: when there is no independent verification of what is in a vial, both kinds of failure can pass undetected. A label can be wrong by accident (substandard) or by design (falsified), and the buyer cannot tell the difference from the label alone.
That is the case for testing the sample rather than trusting the label. Identity testing catches the wrong molecule; content testing catches the wrong amount; purity and safety testing catch the rest. Read together, they are what separates a result from a claim.
WHO fact sheet, Substandard and falsified medical products, December 3, 2024.
Study2017A 2017 JAMA study found only about half of products sold online as SARMs actually contained a SARM, and many held a different unapproved drug instead.
Study2024Test purchases of online 'semaglutide' found purity around 7-14% against 99% advertised, wrong amounts, and elevated endotoxin in one sample.
Study2024How researchers map and audit an unregulated online peptide market, from search surveillance to lab testing.